Abeona Therapeutics is opening The Elisa Linton Center for Rare Disease Therapies, the commercial GMP manufacturing facility for gene and cell therapies in Cleveland, Ohio. The GMP facility will have the capability to manufacture clinical and commercial grade products over Abeona’s multiple programs, including recessive dystrophic epidermolysis bullosa and Sanfilippo syndrome. In addition to the production of the EB-101 and ABO-102 therapies and the AIM AAV vector lab, the 6,000 square foot facility will satisfy the necessary chemistry, manufacturing and controls requirements for commercial development. The second stage of the company’s manufacturing strategy has been initiated with the construction of an additional 20,000 square foot facility that will be used to further meet the anticipated commercial demand for development programs in the longer term.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.